A study evaluating the use of Lipegfilgrastim in patients receiving high-dose chemotherapy and autologous stem cell transplantation to assess the relative benefits of the drug and similarly to compare Lipegfilgrastim with historic controls of multiple myeloma patients who received short-acting agent (filgrastim ) after high-dose chemotherapy
Latest Information Update: 13 Feb 2020
At a glance
- Drugs Filgrastim (Primary) ; Lipegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- 13 Feb 2020 New trial record
- 01 Feb 2020 Results published in the Annals of Hematology